

1. Friedrich M. *Pseudomonas aeruginosa* Infections: Practice Essentials, Background, Pathophysiology. 2017 Aug 8 [cited 2017 Sep 22]; Available from: <http://emedicine.medscape.com/article/226748-overview>
2. Howard A, O'Donoghue M, Feeney A, Sleator RD. *Acinetobacter baumannii*. Virulence. 2012 May 1;3(3):243–50.
3. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick, & Adelberg's Medical Microbiology. Twenty-Sixth. United States of America: McGRAW-HILL; 2013. 245 p.
4. Yanagihara K, Kadota J, Aoki N, Matsumoto T, Yoshida M, Yagisawa M, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: General view of the pathogens' antibacterial susceptibility. *J Infect Chemother Off J Jpn Soc Chemother.* 2015 Jun;21(6):410–20.
5. Bauman RW. Microbiology with Disease by Body System. Fourth. England: Pearson Education Limited; 2015. 601 p.
6. WHO | WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. WHO. [cited 2017 Nov 22]. Available from: <http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/>
7. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. *Infect Control Hosp Epidemiol.* 2008 Nov;29(11):996–1011.
8. Viehman JA, Nguyen M-H, Doi Y. Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant *Acinetobacter baumannii* Infections. *Drugs.* 2014 Aug;74(12):1315–33.
9. Perhimpunan Dokter Paru Indonesia. PNEUMONIA NOSOKOMIAL “PEDOMAN DIAGNOSIS & PENATALAKSANAAN DI INDONESIA” [Internet]. PDPI; 2003 [cited 2017 Sep 7]. Available from: http://pulmonologi.usu.ac.id/images/PDF/Guideline_Pneumonia_Nosokomial _PDPI.pdf
10. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. *Ann Intensive Care.* 2011 Nov 23;1:47.

11. Laurence L. Brunton, Lazo JS, Parker KL. Goodman & Gilman's "The Pharmacological Basic of Theurapeutics." 12th ed. United States of America: McGRAW-HILL; 2011.
12. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, et al. Harrison's principles of internal medicine. 19th ed. Vol. 2. United States of America: McGRAW-HILL Education; 2015.
13. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: Past, Present, and Future v [Internet]. American Society for Microbiology; [cited 2017 Sep 6]. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC55018>
14. Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah S-E, et al. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in *Acinetobacter baumannii*. *J Antimicrob Chemother*. 2017;72(1):153–65.
15. Kayambu G, Boots R, Paratz J. Physical therapy for the critically ill in the ICU: a systematic review and meta-analysis. *Crit Care Med*. 2013 Jun;41(6):1543–54.
16. Chest X-ray interpretation - a structured approach [Internet]. Geeky Medics. 2016 [cited 2018 May 10]. Available from: <https://geekymedics.com/chest-x-ray-interpretation-a-methodical-approach/>
17. The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy - Canadian Journal of Cardiology [Internet]. [cited 2018 May 10]. Available from: [https://www.onlinecjc.ca/article/S0828-282X\(12\)00136-5/abstract](https://www.onlinecjc.ca/article/S0828-282X(12)00136-5/abstract)
18. Todar K. The Normal Bacterial Flora of Humans [Internet]. [cited 2017 Dec 13]. Available from: <http://textbookofbacteriology.net/normalflora.html>
19. Schreiber K, Krieger R, Benkert B, Eschbach M, Arai H, Schobert M, et al. The anaerobic regulatory network required for *Pseudomonas aeruginosa* nitrate respiration. *J Bacteriol*. 2007 Jun;189(11):4310–4.
20. Wikipedia. *Pseudomonas aeruginosa*. In: Wikipedia [Internet]. 2017 [cited 2017 Dec 13]. Available from: https://en.wikipedia.org/w/index.php?title=Pseudomonas_aeruginosa&oldid=814651455
21. Todar K. *Pseudomonas* [Internet]. Todar's Online Textbook of Bacteriology. 2008 [cited 2017 Dec 13]. Available from: http://textbookofbacteriology.net/pseudomonas_3.html
22. Iglewski CVD and BH. Cell-to-Cell Signaling and *Pseudomonas aeruginosa* Infections - Volume 4, Number 4—December 1998 - Emerging Infectious

- Disease journal - CDC. [cited 2017 Dec 13]; Available from: https://wwwnc.cdc.gov/eid/article/4/4/98-0405_article
23. Vital-Lopez FG, Reifman J, Wallqvist A. Biofilm Formation Mechanisms of *Pseudomonas aeruginosa* Predicted via Genome-Scale Kinetic Models of Bacterial Metabolism. PLoS Comput Biol. 2015 Oct;11(10):e1004452.
 24. Rasamiravaka T, Labtani Q, Duez P, El Jaziri M. The Formation of Biofilms by *Pseudomonas aeruginosa*: A Review of the Natural and Synthetic Compounds Interfering with Control Mechanisms [Internet]. BioMed Research International. 2015 [cited 2017 Dec 13]. Available from: <https://www.hindawi.com/journals/bmri/2015/759348/>
 25. Lambert PA. Mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*. J R Soc Med. 2002;95(Suppl 41):22–6.
 26. Sacha P, Wieczorek P, Hauschild T, ZórAWSKI M, Olszańska D, Tryniszewska E. Metallo-beta-lactamases of *Pseudomonas aeruginosa*--a novel mechanism resistance to beta-lactam antibiotics. Folia Histochem Cytobiol. 2008;46(2):137–42.
 27. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in *Pseudomonas aeruginosa*. Hippokratia. 2012;16(4):303–7.
 28. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006 Sep 1;43 Suppl 2:S49-56.
 29. Schweizer HP. Efflux as a mechanism of resistance to antimicrobials in *Pseudomonas aeruginosa* and related bacteria: unanswered questions. Genet Mol Res GMR. 2003 Mar 31;2(1):48–62.
 30. Horii T, Muramatsu H, Morita M, Maekawa M. Characterization of *Pseudomonas aeruginosa* isolates from patients with urinary tract infections during antibiotic therapy. Microb Drug Resist Larchmt N. 2003;9(2):223–9.
 31. Cunha BA. *Acinetobacter*: Background, Pathophysiology, Epidemiology. 2017 Nov 17 [cited 2017 Dec 13]; Available from: <https://emedicine.medscape.com/article/236891-overview>
 32. Wikipedia. *Acinetobacter baumannii*. In: Wikipedia [Internet]. 2017 [cited 2017 Dec 13]. Available from: https://en.wikipedia.org/w/index.php?title=Acinetobacter_baumannii&oldid=812753334
 33. Hashizume T, Ishino F, Nakagawa J, Tamaki S, Matsuhashi M. Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in *Escherichia coli* and

- Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli. *J Antibiot (Tokyo)*. 1984 Apr;37(4):394–400.
34. Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. Current status of newer carbapenems. *Curr Med Chem*. 2009;16(5):564–75.
 35. Zhanell GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. *Drugs*. 2007;67(7):1027–52.
 36. Yamada M. Crystal structures of biapenem and tebipenem complexed with penicillin-binding proteins 2X and 1A from *Streptococcus pneumoniae*. - PubMed - NCBI [Internet]. [cited 2017 Dec 13]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/18391040>
 37. Cottagnoud P, Cottagnoud M, Acosta F, Flatz L, Kühn F, Stucki A, et al. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol*. 2003 Nov;22(11):656–62.
 38. Cirioni O, Ghiselli R, Silvestri C, Kamysz W, Orlando F, Mocchegiani F, et al. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant *Pseudomonas aeruginosa* strain. *Antimicrob Agents Chemother*. 2007 Jun;51(6):2005–10.
 39. Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Häussler S. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol*. 2006 Jan;25(1):25–30.
 40. Guelfi KC, Tognim MCB, Cardoso CL, Gales AC, Carrara-Marrone FE, Garcia LB. In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *J Chemother Florence Italy*. 2008 Apr;20(2):180–5.
 41. Ermertcan S, Hoşgör M, Tünger O, Coşar G. Investigation of synergism of meropenem and ciprofloxacin against *Pseudomonas aeruginosa* and *Acinetobacter* strains isolated from intensive care unit infections. *Scand J Infect Dis*. 2001;33(11):818–21.
 42. Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibáñez-Martínez J, García-Curiel A, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in *Acinetobacter baumannii* experimental pneumonia. *J Antimicrob Chemother*. 2000 Apr;45(4):493–501.

43. Departemen Farmakologik dan Teurapetik Fakultas Kedokteran - Universitas Indonesia. Farmakologi dan Terapi. 6th ed. Jakarta: Badan Penerbit FKUI; 2016. 600–601 p.
44. WebMD LLC.Drugs & Medications [Internet]. [cited 2018 May 10]. Available from: <https://www.webmd.com/drugs/2/drug-13960/meropenem-intravenous/details>
45. WebMD LLC.Drugs & Medications [Internet]. [cited 2018 May 10]. Available from: <https://www.webmd.com/drugs/2/drug-149331/doripenem-intravenous/details>
46. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. *Clin Ther*. 2008 May;30(5):868–83.
47. Infectious Disease Society of America. IDSA : Hospital-Acquired & Ventilator - Associated Pneumonia (HAP/VAP) [Internet]. [cited 2017 Dec 13]. Available from: [http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_by_Organ_System/Lower/Upper_Respiratory/Hospital-Acquired_Ventilator_-Associated_Pneumonia_\(HAP/VAP\)/](http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_by_Organ_System/Lower/Upper_Respiratory/Hospital-Acquired_Ventilator_-Associated_Pneumonia_(HAP/VAP)/)
48. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2016 Sep 1;63(5):e61–111.
49. Andrews JM. Determination of minimum inhibitory concentrations. - PubMed - NCBI. *J Antimicrob Chemother*. 2001;(48):5–16.
50. Patel JB, Weinstein MM, Eliopolus GM. CLSI. Performance Standards for Antimicrobial Susceptibility Testing M1000. 27 ed. United States of America: Clinical and Laboratory Standards Institute; 2017.
51. Tomas MDM, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D, et al. Hospital outbreak caused by a carbapenem-resistant strain of *Acinetobacter baumannii*: patient prognosis and risk-factors for colonisation and infection. *Clin Microbiol Infect*. 2005 Jul 1;11(7):540–6.
52. Castle SC. Clinical Relevance of Age-Related Immune Dysfunction. *Clin Infect Dis*. 2000 Aug 1;31(2):578–85.
53. Colbert JF, Traystman RJ, Poisson SN, Herson PS, Ginde AA. Sex related differences in the risk of hospital-acquired sepsis and pneumonia post-acute ischemic stroke. *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc*. 2016 Oct;25(10):2399–404.

54. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittell M, et al. Treatment of Multidrug-Resistant *Acinetobacter baumannii* Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP. *Clin Infect Dis*. 2003 May 1;36(9):1111–8.
55. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. *Clin Microbiol Rev*. 1993 Oct 1;6(4):428–42.
56. Rowe T, Araujo KLB, Van Ness PH, Pisani MA, Juthani-Mehta M. Outcomes of Older Adults With Sepsis at Admission to an Intensive Care Unit. *Open Forum Infect Dis*. 2016 Jan;3(1):ofw010.
57. Cai B, Echols R, Magee G, Arjona Ferreira JC, Morgan G, Ariyasu M, et al. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *Open Forum Infect Dis* [Internet]. 2017 Aug 16 [cited 2018 May 23];4(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629822/>
58. Rodrigo-Troyano A, Suarez-Cuartin G, Peiró M, Barril S, Castillo D, Sanchez-Reus F, et al. *Pseudomonas aeruginosa* resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. *Respirol Carlton Vic*. 2016;21(7):1235–42.
59. Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. *Antimicrob Agents Chemother*. 2011 Apr;55(4):1606–10.
60. RxKinetics. PK/PD Approach to Antibiotic Therapy Review [Internet]. [cited 2018 May 20]. Available from: http://www.rxkinetics.com/antibiotic_pk_pd.html
61. Oshima K, Nakamura S, Iwanaga N, Takemoto K, Miyazaki T, Yanagihara K, et al. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* [Internet]. 2016 Dec 27 [cited 2018 May 19];61(1). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192154/>
62. Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, et al. Combating carbapenem-resistant *Acinetobacter baumannii* by an optimized imipenem plus tobramycin dosage regimen – prospective validation via hollow fiber infection and mathematical modeling. *Antimicrob Agents Chemother*. 2018 Jan 16;AAC.02053-17.

63. Nakamura A, Hosoda M, Kato T, Yamada Y, Itoh M, Kanazawa K, et al. Combined effects of meropenem and aminoglycosides on *Pseudomonas aeruginosa* in vitro. *J Antimicrob Chemother.* 2000 Dec;46(6):901–4.
64. Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB. Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2015 Apr 1;59(4):2286–98.